Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 and Eribulin in Metastatic Breast Cancer
NCT01596751Phase 2Completed
- Sponsor
- Hope Rugo
- Start
- Jul 2012
- Primary completion
- Jul 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of pexidartinib in breast cancer (4 arms), sponsored by Hope Rugo. Primary endpoints: Maximum Tolerated Dose at Day 21, Dose-Limiting Toxicities at Day 21 and 1 more. Started Jul 2012; status: completed.
02
Drugs
pexidartinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01596751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01596751.